Glucose control in the older patient: From intensive, to effective and safe

Aging Clinical and Experimental Research

Volumn 22, Issue 4, 2010, Pages 274-280

  Dominguez, Ligia J ^a   Paolisso, Giuseppe ^b   Barbagallo, Mario ^a  

^a UNIVERSITY OF PALERMO   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Dementia; Elderly; Falls; Hypoglycemia; Type 2 diabetes

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; GLIMEPIRIDE; GLUCOSE; INSULIN; INSULIN GLARGINE; METFORMIN;

ADULT; AGED; BREAST CANCER; CARDIOVASCULAR DISEASE; CEREBROVASCULAR DISEASE; COMORBIDITY; CRITICALLY ILL PATIENT; DEMENTIA; DIABETES MELLITUS; DISABILITY; DISEASE ASSOCIATION; FALLING; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEART ARRHYTHMIA; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INDIVIDUALIZATION; MORBIDITY; MORTALITY; MOTIVATION; NEOPLASM; NON INSULIN DEPENDENT DIABETES MELLITUS; NORMAL VALUE; PRACTICE GUIDELINE; QT INTERVAL; QT PROLONGATION; RISK; SECONDARY PREVENTION; SHORT SURVEY; VASCULAR DISEASE;

ACCIDENTAL FALLS; ADULT; AGE FACTORS; AGED; BLOOD GLUCOSE; DEMENTIA; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MIDDLE AGED; NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 78650725784     PISSN: 15940667     EISSN: 17208319     Source Type: Journal    
DOI: 10.3275/6629     Document Type: Short Survey

References (41)

1. van den Berghe G, Wouters P, Weekers F et al. Intensive insulin therapy in the critically ill patients. N Engl J Med 2001; 345: 1359-67.
2. Wiener RS, Wiener DC, Larson RJ. Benefits and risks of tight glucose control in critically ill adults: a meta-analysis. JAMA 2008; 300: 933-44.
3. Finfer S, Chittock DR, Su SY et al. Intensive versus conventional glucose control in critically ill patients. N Engl J Med 2009; 360: 1283-97.
4. Abbatecola AM, Maggi S, Paolisso G. New approaches to treating type 2 diabetes mellitus in the elderly: role of incretin therapies. Drugs Aging 2008; 25: 913-25.
5. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339: 229-34.
6. Almdal T, Scharling H, Jensen JS, Vestergaard H. The independent effect of type 2 diabetes mellitus on ischemic heart disease, stroke, and death: a population-based study of 13,000 men and women with 20 years of follow-up. Arch Intern Med 2004; 164: 1422-6.
7. Selvin E, Marinopoulos S, Berkenblit G et al. Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med 2004; 141: 421-31.
8. Gerstein HC, Pogue J, Mann JF et al. The relationship between dysglycaemia and cardiovascular and renal risk in diabetic and non-diabetic participants in the HOPE study: a prospective epidemiological analysis. Diabetologia 2005; 48: 1749-55.
9. Stratton IM, Adler AI, Neil HA et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000; 321: 405-12.
10. Gerstein HC, Miller ME, Byington RP et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358: 2545-59.
11. Patel A, MacMahon S, Chalmers J et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358: 2560-72.
12. Duckworth W, Abraira C, Moritz T et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009; 360: 129-39.
13. Gill GV, Woodward A, Casson IF, Weston PJ. Cardiac arrhythmia and nocturnal hypoglycaemia in type 1 diabetes - the 'dead in bed' syndrome revisited. Diabetologia 2009; 52: 42-5.
14. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007; 356: 2457-71. (Pubitemid 46919772)
15. Mannucci E, Monami M, Di Bari M et al. Cardiac safety profile of rosiglitazone A comprehensive meta-analysis of randomized clinical trials. Int J Cardiol 2010; 143: 135-40.
16. Home PD, Pocock SJ, Beck-Nielsen H et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet 2009; 373: 2125-35.
17. Bodmer M, Meier C, Kraenzlin ME, Meier CR. Risk of fractures with glitazones: a critical review of the evidence to date. Drug Saf 2009; 32: 539-47.
18. Arcaro G, Cretti A, Balzano S et al. Insulin causes endothelial dysfunction in humans: sites and mechanisms. Circulation 2002; 105: 576-82. (Pubitemid 34123431)
19. Ohman MK, Wright AP, Wickenheiser KJ, Luo W, Eitzman DT. Visceral adipose tissue and atherosclerosis. Curr Vasc Pharmacol 2009; 7: 169-79.
20. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-86.
21. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-53.
22. Nathan DM, Cleary PA, Backlund JY et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005; 353: 2643-53.
23. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008; 359: 1577-89.
24. Montori VM, Gandhi GY, Guyatt GH. Patient-important outcomes in diabetes - time for consensus. Lancet 2007; 370: 1104-6.
25. Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008; 358: 580-91.
26. Ray KK, Seshasai SR, Wijesuriya S et al. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet 2009; 373: 1765-72.
27. Malmberg K, Ryden L, Efendic S et al. Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): effects on mortality at 1 year. J Am Coll Cardiol 1995; 26: 57-65.
28. Malmberg K, Ryden L, Wedel H et al. intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidity. Eur Heart J 2005; 26: 650-61.
29. Mellbin LG, Malmberg K, Norhammar A, Wedel H, Ryden L. The impact of glucose lowering treatment on long-term prognosis in patients with type 2 diabetes and myocardial infarction: a report from the DIGAMI 2 trial. Eur Heart J 2008; 29: 166-76.
30. Giovannucci E, Michaud D. The role of obesity and related metabolic disturbances in cancers of the colon, prostate, and pancreas. Gastroenterology 2007; 132: 2208-25.
31. Hemkens LG, Grouven U, Bender R et al. Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study. Diabetologia 2009; 52: 1732-44.
32. Jonasson JM, Ljung R, Talback M, Haglund B, Gudbjornsdottir S, Steineck G. Insulin glargine use and short-term incidence of malignancies-a population-based follow-up study in Sweden. Diabetologia 2009; 52: 1745-54.
33. Colhoun HM. Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group. Diabetologia 2009; 52: 1755-65.
34. Currie CJ, Poole CD, Gale EA. The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia 2009; 52: 1766-77.
35. Smith U, Gale EA. Does diabetes therapy influence the risk of cancer? Diabetologia 2009; 52: 1699-708.
36. Schwartz AV, Hillier TA, Sellmeyer DE et al. Older women with diabetes have a higher risk of falls: a prospective study. Diabetes Care 2002; 25: 1749-54.
37. Schwartz AV, Vittinghoff E, Sellmeyer DE et al. Diabetes-related complications, glycemic control, and falls in older adults. Diabetes Care 2008; 31: 391-6.
38. Nelson JM, Dufraux K, Cook PF. The relationship between glycemic control and falls in older adults. J Am Geriatr Soc 2007; 55: 2041-4.
39. Whitmer RA, Karter AJ, Yaffe K, Quesenberry CP Jr, Selby JV. Hypoglycemic episodes and risk of dementia in older patients with type 2 diabetes mellitus. JAMA 2009; 301: 1565-72.
40. Frolich L, Blum-Degen D, Bernstein HG et al. Brain insulin and insulin receptors in aging and sporadic Alzheimer's disease. J Neural Transm 1998; 105: 423-38. (Pubitemid 28365027)
41. Cook DG, Leverenz JB, McMillan PJ et al. Reduced hippocampal insulin-degrading enzyme in late-onset Alzheimer's disease is associated with the apolipoprotein E-epsilon4 allele. Am J Pathol 2003; 162: 313-9.